{"entity":{"id":"nct04592653","kind":"trial","name":"Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Mural Oncology, Inc, active and no longer recruiting.","summary":"Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) is a phase 1/2 interventional study registered as NCT04592653 by Mural Oncology, Inc, with 78 participants enrolled, started 2020-09-30 and due to reach its primary completion in 2024-07. Interventions recorded: Nemvaleukin alfa and Pembrolizumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04592653","url":"https://clinicaltrials.gov/study/NCT04592653"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04592653","phase":"1/2","setting":"Clinical and Immunologic Activity of Nemvaleukin Alfa With Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3","sponsor":"Mural Oncology, Inc","enrolled":78,"outcomes":[]},"route":"/trials/nct04592653/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}